Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Osteosarcoma

• A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Advanced Bone and Soft Tissue Tumors
• Cabozantinib With Ifosfamide in Ewing's Sarcoma and Osteosarcoma
• Tucidinostat Plus Apatinib for Advanced Osteosarcoma
• Safety and Efficacy of NK510 to Treat Osteosarcoma and Soft Tissue Sarcoma
• A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Bone and Soft Tissue Tumors
• HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas
• Culturally Adapted Mobile Treatment of Chronic Pain in Adolescent Survivors of Pediatric Bone Sarcoma
• Immunotherapy for Recurrent Osteogenic Sarcoma
• Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Advanced Renal Cell Carcinoma, Mesothelioma and Osteosarcoma
• A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma
• A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma
• A First-In-Human Phase 1 Trial of T-Cell Membrane-Anchored Tumor Targeted Il12 (Attil12)- T-Cell Therapy in Subjects With Advanced/Metastatic Soft Tissue and Bone Sarcoma
• A Study of Sulfatinib on Relapsed or Refractory Drug Resistant Osteosarcoma
• Assessing Clinical Trial Outcome of Patients With Relapsed/Refractor Metastatic Osteosarcoma in Adolescents and Adults
• Qarziba for Patients in Relapsed/Refractory High-grade Osteosarcoma
• Efficacy of Tranexamic Acid in Preventing Post Operative Blood Loss in Bone Sarcoma Patient
• Regorafenib in Patients With Refractory Primary Bone Tumors
• A Randomised Placebo-Controlled Study of Use of GnRHa During Chemotherapy for Fertility Protection of Young Women With Cancer
• A Phase I Feasibility And Safety Study of Fluorescein-Specific (FITC-Ew) CAR T Cells In Combination With Parenterally Administered Folate-Fluorescein (UB-TT170) For Osteogenic Sarcoma
• Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors
• Apatinib With Ifosfamide Plus Etoposide for Relapsed or Refractory Osteosarcoma (OAIE)
• Combination of Pembrolizumab and Cabozantinib in Patients With Advanced Sarcomas
• Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma
• Surufatinib in Patients With Osteosarcoma and Soft Tissue Sarcoma
• A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors
• Neoadjuvant Combination of Doxorubicin, Cisplatin and Methotrexate in Patients Aged 24-40 Years With Primary Bone Tumors
• Perioperative Use of Tranexamic (TXA) in Bone Tumor Surgery Reduce Blood Loss and Transfusion Requirements.
• Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcoma, TACOS Study
• Osteosarcoma Maintenance Therapy With OST31-164
• Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
• B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
• A Study to Evaluate the Safety and Efficacy of ALMB-0168 in Patients With Osteosarcoma
• Gemcitabine With Ascorbate Including Adolescents
• CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
• Clinical Study of CD276 Targeted Autologous Chimeric Antigen Receptor T Cell Infusion in Patients With CD276 Positive Advanced Solid Tumor
• IBI188 Combination Therapy in Solid Tumors
• Indo-cyanine Green (ICG) in Paediatric Oncology MIS
• Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
• A Study of ZN-c3 in Combination With Gemcitabine in Subjects With Osteosarcoma
• Apatinib Plus IE Chemotherapy (Ifosfamide and Etoposide) for Relapsed or Refractory Osteosarcoma
• SARC038: Phase 2 Study of Regorafenib and Nivolumab in Osteosarcoma
• Metformin as Maintenance Therapy in Patients With Bone Sarcoma and High Risk of Relapse
• Efficacy of Regorafenib Combined With Best Supportive Care as Maintenance Treatment in High Grade Bone Sarcomas Patients
• TQB3525 for Advanced Bone Sarcomas With PI3KA Mutations or PTEN Loss
• Apatinib + Ifosfamide and Etoposide for Relapsed or Refractory Osteosarcoma
• Cabozantinib With Topotecan-Cyclophosphamide
• Gemcitabine Plus Ascorbate for Sarcoma in Adults (Pilot)
• Selinexor Plus Gemcitabine in Selected Advanced Soft-tissue Sarcoma and Osteosarcoma
• Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults With Relapsed/Refractory Osteosarcoma and Neuroblastoma, The GD2-CAR PERSIST Trial
• Olaparib With Ceralasertib in Recurrent Osteosarcoma
• 18F-FTC-146 PET/CT in Newly-Diagnosed Osteosarcoma
• Comparison of MAPI+Camrelizumab Versus API+Apatinib Versus MAPI in Patients With a Poor Response to Preoperative Chemotherapy for Newly Diagnosed High-grade Osteosarcoma
• Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial
• Phase II Clinical Trial Scheme of Ganoderma Lucidum Spore Powder for Postoperative Chemotherapy of Osteosarcoma
• A Phase I Clinical Trial of Neoadjuvant Chemotherapy With/Without SPIONs/SMF for Patients With Osteosarcoma
• Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy in the Treatment of Osteosarcoma
• Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial
• Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)
• BIO-11006 for Osteosarcoma and Ewing's Sarcoma Lung Metastases
• A Study to Compare the Efficacy and Safety of Ifosfamide and Etoposide With or Without Lenvatinib in Children, Adolescents and Young Adults With Relapsed and Refractory Osteosarcoma
• Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas
• Famitinib Plus Camrelizumab & Famitinib Alone & Famitinib Plus Ifosfamide in Advanced Osteosarcoma
• Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration
• Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Soft Tissue or Bone Sarcoma Metastatic to the Lungs
• Glucarpidase After High-Dose Methotrexate in Patients With Osteosarcoma
• Zoledronic Acid in Decrease the Lung Metastatic Rate of Osteosarcoma
• Transcatheter Intra-arterial Limb Infusion of Cisplatin for Extremity Osteosarcoma
• Losartan + Sunitinib in Treatment of Osteosarcoma
• Natalizumab in Recurrent, Refractory or Progressive Pulmonary Metastatic Osteosarcoma
• Pulmonary Resectable Metastases of Osteosarcoma With Apatinib and CHemotherapy
• Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma
• M6620 (VX-970) in Selected Solid Tumors
• Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
• 9-ING-41 in Patients With Advanced Cancers
• Mifamurtide Combined With Post-operative Chemotherapy for Newly Diagnosed High Risk Osteosarcoma Patients
• C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N)
• Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcoma
• A Dose Finding Study of CycloSam® Combined With External Beam Radiotherapy
• Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma
• Gemcitabine, Docetaxel, and Hydroxychloroquine in Treating Participants With Recurrent or Refractory Osteosarcoma
• Radiotherapy Concurrent With Apatinib in Advanced Soft Tissue and Bone Sarcomas of Head and Neck--RASS Study
• Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)
• Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1.
• Dose Escalation Study of CLR 131 in Children, Adolescents, and Young Adults With Relapsed or Refractory Malignant Tumors Including But Not Limited to Neuroblastoma, Rhabdomyosarcoma, Ewings Sarcoma, and Osteosarcoma
• Gemcitabine Plus Ascorbate for Sarcoma in Adults
• ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma, Osteosarcoma, Ewing's Sarcoma, and Small Cell Lung Cancer
• LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas
• Feasibility Study of Interval Compressed Regimen Using Four-drugs for Osteosarcoma
• Timing of Surgery in Nonmetastatic Osteosarcoma of the Pelvis and Sacrum
• Apatinib Plus Anti-PD1 Therapy for Advanced Osteosarcoma
• Trial of Sunitinib Plus Nivolumab After Standard Treatment in Advanced Soft Tissue and Bone Sarcomas
• Low Molecular Weight Heparin (LMWH) vs Aspirin for Venous Thromboembolism (VTE) Prophylaxis in Orthopaedic Oncology
• Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
• Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
• Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)
• Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
• Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)
• Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
• Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
• Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers
• Apatinib Second Line Treatment for Advanced Osteosarcoma and Soft Tissue Sarcomas ,Openting ,Single Center, One-armed Clinical Study.
• To Evaluate the Efficacy of NY-ESO-1-specific T Cell Receptor Affinity Enhancing Specific T Cell in Solid Tumors
• Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
• A Study of Pembrolizumab in Patients With Relapsed Or Metastatic Osteosarcoma Not Eligible for Curative Surgery
• A Phase II Trial of Avelumab in Patients With Recurrent or Progressive Osteosarcoma
• Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors
• A Phase II of Nivolumab Plus Ipilimumab in Non-resectable Sarcoma and Endometrial Carcinoma
• Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma
• Evaluating Stereotactic Body Radiation Therapy for Oligometastatic Disease of the Bone
• Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
• Co-treatment With GnRH Analogs on the Ovarian Reserve in Young Women Treated With Alkylating Agents for Cancer
• In Vivo Lung Perfusion for Pulmonary Metastases of Sarcoma
• Phase II Trial for the Treatment of Relapsed Osteosarcoma
• Apatinib for Advanced Osteosarcoma After Failure of Standard Multimodal Therapy
• Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors
• Abemaciclib in Children With DIPG or Recurrent/Refractory Solid Tumors
• HIFU Hyperthermia With Liposomal Doxorubicin (DOXIL) for Relapsed or Refractory Pediatric and Young Adult Solid Tumors
• A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric Refractory Solid Tumors
• Metronomic Chemotherapy in Patients With Advanced Solid Tumor With Bone Metastasis and Advanced Pretreated Osteosarcoma
• Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
• Humanized Monoclonal Antibody 3F8 (Hu3F8) With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in the Treatment of Recurrent Osteosarcoma
• Glembatumumab Vedotin in Treating Patients With Recurrent or Refractory Osteosarcoma
• Study Evaluating the Biologic Activity of Guanabenz in Bone Metastasis
• A Eurosarc Study of Mifamurtide in Advanced Osteosarcoma (MEMOS)
• Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma
• Trial With Gemcitabine and Rapamycin in Second Line of Metastatic Osteosarcoma
• Simvastatin With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors
• A Phase II Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas
• A Retrospective Non-intervention Study to Characterize FOlate Rescue Treatment in Osteosarcoma Patients Treated With HDMTX
• Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas
• SARC028: A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas
• Prospective Clinical Trial Evaluating Metronomic Chemotherapy in Patients With High-grade, Operable, Non-metastatic Osteosarcoma of the Extremity
• Cabozantinib S-malate in Treating Patients With Relapsed Osteosarcoma or Ewing Sarcoma
• Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies
• Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery
• A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors
• Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors
• A Clinical Trial on Efficacy and Safety for Lobaplatin and Gemcitabine in Combination With Docetaxel in the Second-line Treatments on Advanced Osteosarcoma
• Eribulin Mesylate in Treating Patients With Recurrent or Refractory Osteosarcoma
• NAC to Prevent Cisplatin-induced Hearing Loss
• SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes
• Will Glucarpidase After Methotrexate Treatment for Bone Sarcoma Lead to Fewer Side Effects and Reduce Chemotherapy Delays?
• Phase 1 Study of MM-398 Plus Cyclophosphamide in Pediatric Solid Tumors
• Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors
• Investigation of [6R] 5,10-methylenetetrahydrofolate (Arfolitixorin) as Rescue Therapy for Osteosarcoma Patients Treated With HDMTX.
• Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors
• iC9-GD2-CAR-VZV-CTLs/Refractory or Metastatic GD2-positive Sarcoma and Neuroblastoma
• Combination of External Beam Radiotherapy With 153Sm-EDTMP to Treat High Risk Osteosarcoma
• Preventing Nephrotoxicity and Ototoxicity From Osteosarcoma Therapy
• Phase I Dose Escalation of Monthly Intravenous Ra-223 Dichloride in Osteosarcoma
• RAD001 in Advanced Sarcoma
• Phase II Open Label, Non-randomized Study of Sorafenib and Everolimus in Relapsed and Non-resectable Osteosarcoma
• Dendritic Cell Vaccine for Children and Adults With Sarcoma
• Study of Pazopanib in the Treatment of Osteosarcoma Metastatic to the Lung
• A Clinical Research on the Relation of Blood Drug Concentration and Calcium Folinate Rescued in High-dose MTX Therapy
• Clinical Trial of Lithium Carbonate Combined With Neo-adjuvant Chemotherapy to Treat Osteosarcoma
• Anti-Angiogenic Therapy Post Transplant (ASCR) for Pediatric Solid Tumors
• Phase 2 Study of Inhaled Lipid Cisplatin in Pulmonary Recurrent Osteosarcoma
• Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
• Aerosol IL-2 for Pulmonary Metastases
• Compound 31543 (Calcitriol, USP) in Patients Receiving Taxane-based Chemotherapy Regimens for Advanced or Recurrent Disease
• Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery
• Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma
• Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors
• Eltrombopag for the Prevention of Chemotherapy Induced Thrombocytopenia
• ABCB1/P-glycoprotein Expression as Biologic Stratification Factor for Patients With Non Metastatic Osteosarcoma
• Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.
• Differentiation of Bone Sarcomas and Osteomyelitis With Ferumoxytol-Enhanced MRI
• Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors
• Cyclophosphamide, Doxorubicin, Vincristine w/ Irinotecan and Temozolomide in Ewings Sarcoma
• A Study of Pre-Operative Treatment of Newly-Diagnosed, Surgically-Resectable Osteosarcoma With Doxorubicin, Ifosfamide, Etoposide, and Cisplatin With Early Metabolic Assessment of Response
• Intravenous Palifosfamide-tris in Combination With Etoposide and Carboplatin in Patients With Malignancies
• RO4929097 in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell Leukemia
• Phase II Study of Everolimus in Children and Adolescents With Refractory or Relapsed Osteosarcoma
• Surveillance Study of Patients With Newly Diagnosed Osteosarcoma
• Outpatient Administration of High Dose Methotrexate (HD MTX) in Patients With Osteosarcoma
• Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
• Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma
• A Phase I Study of Pazopanib as a Single Agent for Children With Refractory Solid Tumors
• Temsirolimus and Cixutumumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Soft Tissue Sarcoma or Bone Sarcoma
• A Study of Endostar Combined With Chemotherapy for Treatment of Osteosarcoma
• Adjuvant High-Dose Thiotepa and Stem Cell Rescue Associated With Conventional Chemotherapy in Relapsed Osteosarcoma
• A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006)
• Sorafenib in Relapsed High Grade Osteosarcoma
• Methionine PET/CT Studies In Patients With Cancer
• Dacarbazine for Metastatic Soft Tissue and Bone Sarcoma
• A Placebo-Controlled Study of Saracatinib (AZD0530) in Patients With Recurrent Osteosarcoma Localized to the Lung
• A Phase II Study of Oral Cyclophosphamide and Sirolimus (OCR) in Advanced Sarcoma
• Zoledronic Acid and Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Osteosarcoma
• Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma
• Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy
• Evaluation of Zoledronic Acid as a Single Agent or as an Adjuvant to Chemotherapy in High Grade Osteosarcoma
• Doxorubicin With Cisplatin, High-Dose Methotrexate, and Additional Risk-Adapted Outpatient Chemotherapy
• A Study of Bevacizumab in Combination With Chemotherapy for Treatment of Osteosarcoma
• Combination Chemotherapy in Treating Patients Undergoing Surgery for Newly Diagnosed High-Grade Osteosarcoma
• Open-label Leucovorin Pharmacokinetic Study in Patients Receiving High Dose Methotrexate With or Without Voraxaze
• High Dose Methotrexate With Leucovorin Rescue With or Without Glucarpidase in Osteosarcoma
• Mifamurtide (L-MTP-PE) for High-Risk Osteosarcoma
• Phase II Study of Chemotherapy and Pamidronate for the Treatment of Newly Diagnosed Osteosarcoma
• Combination Chemotherapy and Dexrazoxane Followed by Surgery and Radiation Therapy in Treating Patients With Advanced Soft Tissue Sarcoma or Recurrent Bone Sarcoma
• Ridaforolimus in Treatment of Sarcoma-SUCCEED (Sarcoma Multi-Center Clinical Evaluation of the Efficacy of Ridaforolimus)(8669-011 AM6)
• Dalteparin in Preventing DVT in Participants With Cancer
• Chemotherapy for Patients With Osteosarcoma
• A Study of Pemetrexed in Children With Recurrent Cancer
• Recombinant Interferon Alpha and Etoposide in Relapsed Osteosarcoma
• Combined Chemotherapy With or Without Zoledronic Acid for Patients With Osteosarcoma
• HGS-ETR2 to Treat Children With Solid Tumors
• Clinical Studies of Gemcitabine-Oxaliplatin
• Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma
• Ixabepilone in Treating Young Patients With Refractory Solid Tumors
• Sorafenib in Treating Patients With Soft Tissue Sarcomas (Extremity Sarcoma Closed to Entry as of 5/30/07)
• Samarium Sm 153 and Stem Cell Transplant Followed By Radiation Therapy Patients With Osteosarcoma
• Recombinant Human Thrombopoietin in Children Receiving Ifosfamide, Carboplatin, and Etoposide Chemotherapy
• Study of Vinorelbine and Cyclofosfamide Among Patients With Refractory Tumours or in Relapse
• Comparison of High-Dose Methotrexate (HDM) Plus Doxorubicin to HDM Plus Etoposide-Ifosfamide in Osteosarcoma Children
• Osteosarcoma1999-A Study Of Intensive Chemotherapy for Osteosarcoma
• Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma
• ZD1839 and Oral Irinotecan in Treating Young Patients With Refractory Solid Tumors
• Enbrel Versus Placebo With Radiation Therapy to Combat Fatigue and Cachexia
• Methotrexate, Trimetrexate Glucuronate, and Leucovorin in Treating Patients With Refractory or Recurrent Osteosarcoma
• Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma
• Inhalation SLIT Cisplatin (Liposomal) for the Treatment of Osteosarcoma Metastatic to the Lung
• Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas
• Tanespimycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors
• Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED)
• Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment
• Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors
• Gemcitabine and Docetaxel in Treating Patients With Recurrent Osteosarcoma (Closed to Accrual as of 12/21/06) or Ewing's Sarcoma or Unresectable or Locally Recurrent Chondrosarcoma
• Liposomal Vincristine for Pediatric and Adolescent Patients With Relapsed Malignancies
• Imatinib Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma or Bone Sarcoma
• Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood
• Chemotherapy With or Without Trastuzumab in Treating Patients With Metastatic Osteosarcoma
• Vaccine Therapy in Treating Patients With Metastatic Cancer
• Combination Chemotherapy Before and After Surgery in Treating Patients With Osteosarcoma
• Liposomal Doxorubicin in Treating Children With Refractory Solid Tumors
• Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas
• Ecteinascidin 743 in Treating Patients With Previously Treated Metastatic Osteosarcoma
• 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma
• Irinotecan in Treating Children With Refractory Solid Tumors
• Combination Chemotherapy Plus Dexrazoxane in Treating Patients With Newly Diagnosed Nonmetastatic Osteosarcoma
• Combination Chemotherapy and Surgery in Treating Patients With Newly Diagnosed Metastatic Osteosarcoma
• Combination Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia, Osteosarcoma, or Non-Hodgkin's Lymphoma
• Combination Chemotherapy and Surgery With or Without G-CSF in Treating Patients With Osteosarcoma
• A Phase I Study of OncoLAR® (Registered Trademark) (NSC 685403) With/Without Tamoxifen in Patients With Osteosarcoma
• Osteosarcoma Study #2: A Randomized Trial of Pre-Surgical Chemotherapy vs. Immediate Surgery and Adjuvant Chemotherapy in the Treatment of Non-Metastatic Osteosarcoma. A Pediatric Oncology Group Phase III Study
• A Pilot Study for the Treatment of Patients With Metastatic and High Risk Sarcomas and Primitive Neuroectodermal Tumors